Effect of dual PPAR-α/γ agonist saroglitazar on diabetic retinopathy and oxygen-induced retinopathy

Burden of Complications in U.S. Adults With Young-Onset Type 2 or Type 1 Diabetes

(2020) Michael Fang et al.   DIABETES CARE

Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)

(2020) Manjunath Krishnappa et al.   Cardiovascular Diabetology

PPARs and Angiogenesis—Implications in Pathology

(2020) Nicole Wagner et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Saroglitazar attenuates renal fibrosis induced by unilateral ureteral obstruction via inhibiting TGF-β/Smad signaling pathway

(2020) Mirhan N. Makled et al.   LIFE SCIENCES

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease

(2020) Divya P. Kumar et al.   Scientific Reports

Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial

(2019) Nimisha Jain et al.   Scientific Reports

Saroglitazar reduces obesity and associated inflammatory consequences in murine adipose tissue

(2018) Durgesh Kumar et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Role of Inflammation in Diabetic Retinopathy

(2018) Anne Rübsam et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Distinct but complementary contributions of PPAR isotypes to energy homeostasis

(2017) Vanessa Dubois et al.   JOURNAL OF CLINICAL INVESTIGATION

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

(2017) Mukul R. Jain et al.   LIVER INTERNATIONAL

Global aetiology and epidemiology of type 2 diabetes mellitus and its complications

(2017) Yan Zheng et al.   Nature Reviews Endocrinology

Diabetic retinopathy

(2016) Tien Y. Wong et al.   Nature Reviews Disease Primers

Saroglitazar for the treatment of dyslipidemia in diabetic patients

(2015) Shashank R Joshi   EXPERT OPINION ON PHARMACOTHERAPY

Diabetic Retinopathy

(2015) Andrew M. Hendrick et al.   PRIMARY CARE

Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis

(2014) Fengyun Dong et al.   CANCER BIOLOGY & THERAPY

The Effects of Medical Management on the Progression of Diabetic Retinopathy in Persons with Type 2 Diabetes

(2014) Emily Y. Chew et al.   OPHTHALMOLOGY

Oxidative stress in angiogenesis and vascular disease

(2013) Y.-W. Kim et al.   BLOOD

Pathogenic role of diabetes-induced PPAR-  down-regulation in microvascular dysfunction

(2013) Y. Hu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions

(2013) Ingeborg Klaassen et al.   PROGRESS IN RETINAL AND EYE RESEARCH

Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models

(2012) Ying Chen et al.   DIABETES

Inhibition of microsomal triglyceride transfer protein improves insulin sensitivity and reduces atherogenic risk in Zucker fatty rats

(2011) Vipin Dhote et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Aliskiren reduces vascular pathology in diabetic retinopathy and oxygen-induced retinopathy in the transgenic (mRen-2)27 rat

(2011) J. L. Wilkinson-Berka et al.   DIABETOLOGIA

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

Diabetic retinopathy

(2010) Ning Cheung et al.   LANCET

PPARγ ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis

(2008) Ahmad Aljada et al.   ANGIOGENESIS

Rosiglitazone and Delayed Onset of Proliferative Diabetic Retinopathy

(2008) Lucy Q. Shen   ARCHIVES OF OPHTHALMOLOGY